FDA gives Durham's BioCryst green light to resume trial enrollment

A Durham drugmaker can resume enrolling patients in multiple clinical trials after getting the OK from regulators.

Source: bizjournals.com Health Care:Physician Practices headlines - August 4, 2022 Category: American Health Authors: Zac Ezzone Source Type: news